Lung India最新文献

{"title":"Criss-cross pulmonary arteries with a plethora of other anomalies in an adult.","authors":"Archit Dikshit, Megha M Sheth, Saurabh Deshpande, Dinesh Patel, Pratyaksha Rana","doi":"10.4103/lungindia.lungindia_85_24","DOIUrl":"10.4103/lungindia.lungindia_85_24","url":null,"abstract":"","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 5","pages":"394-395"},"PeriodicalIF":1.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 58-year-old man with unexplained cough and dyspnoea.","authors":"Ganesh Narwade, Rohit Kumar, Manu Madan, A J Mahendran, Pranav Ish, Alpana Srivastava, Nitesh Gupta","doi":"10.4103/lungindia.lungindia_132_24","DOIUrl":"10.4103/lungindia.lungindia_132_24","url":null,"abstract":"","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 4","pages":"305-306"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Profile of patients referred for lung transplant and their transplant-free survival.","authors":"Vidushi Rathi, Pawan Tiwari, Sandeep Seth, Vijay Hadda, Karan Madan, Shubham Agarwal, Arti Vij, Milind Hote, Manoj Sahu, Saurabh Mittal, Randeep Guleria, Shivam Pandey, Ravindra M Pandey, Anant Mohan","doi":"10.4103/lungindia.lungindia_515_23","DOIUrl":"10.4103/lungindia.lungindia_515_23","url":null,"abstract":"<p><strong>Introduction: </strong>Lung transplant (LTx) is a potential treatment option for all patients with chronic, end-stage respiratory disease, who are refractory to optimal medical therapy or where no medical therapy exists. In India, LTx is still in its evolving stages and published literature is sparse. The current study was carried out to study the selection criteria for lung transplant and to evaluate the clinical and socio-economic profile of patients referred for the same at a tertiary health care facility.</p><p><strong>Methods: </strong>The study was a descriptive, prospective, observational study. All adults referred for lung transplant were evaluated for clinical and laboratory profiles. All enrolled patients were assessed for presence of referral criteria, listing criteria, contraindications, and willingness for lung transplant. These patients were followed up for 2 years for transplant-free survival, and the Cox proportional hazards model was used to determine independent predictors of all-cause mortality.</p><p><strong>Results: </strong>A total of 103 were included in study. The most common diagnosis was interstitial lung disease (57.2%), followed by bronchiectasis (17.5%) and COPD (13.6%). Most patients were referred for LTx at an advanced stage as 90% met listing criteria. Fifty-four (52.4%) patients had an absolute or relative contraindication to transplant; however, the majority of those contraindications were modifiable. Patients with a lower socio-economic status were less likely to be willing for LTx. The median survival was 757 days. A 6-minute walk distance (6MWD) lesser than 250 m was found to be an independent predictor of mortality.</p><p><strong>Conclusion: </strong>Making patients aware about lung transplant early in their treatment may give them sufficient time to come to terms with their disease and understand the risk and benefits associated. Efforts should be focused on screening and early treatment of reversible contraindications for the eligible patients. Patients with 6MWD < 250 m are at increased risk of mortality.</p>","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 4","pages":"265-271"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302780/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wean early leave early: Apt strategy for weaning from non-invasive ventilation.","authors":"Sebin J Thampan, Arun Prasath, Jackin Moses, King H Kisku, Pinkutty Sagar, Kandasamy Ravichandran","doi":"10.4103/lungindia.lungindia_15_24","DOIUrl":"10.4103/lungindia.lungindia_15_24","url":null,"abstract":"<p><strong>Background: </strong>Weaning protocols from Non-invasive ventilation (NIV) are scant. We set out to study a protocol that was different from the British Thoracic Society protocol and lay down a weaning protocol from NIV in patients with Acute acidotic hypercapnic respiratory failure (AAHRF).</p><p><strong>Materials and methods: </strong>Patients admitted with AAHRF and treated with NIV (baseline pH<7.35, PaCO2 >45 mmHg, and not requiring intubation) at a tertiary care teaching hospital, after taking into consideration the inclusion and the exclusion criteria were randomised in to one of the two group of weaning form NIV and serial ABGs were monitored.</p><p><strong>Results: </strong>The primary outcome of the study shows that there was no significant differences in the success rates of weaning from NIV in both the arms. The secondary outcome shows a few factors such as age, gender, SAPS2 score having an effect on the determination of weaning failure.</p><p><strong>Conclusion: </strong>Our study showed that both weaning by duration reduction and pressure reduction had equal success rates but a point on noting the SAPS II score on admission and the age of a particular patient will help decide on weaning initiation.CTRI/2019/12/022560 [Registered on: 30/12/2019].</p>","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 4","pages":"284-287"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302777/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A young male with non-resolving consolidation and hepatosplenomegaly.","authors":"Pradeep Bajad, Sourabh Pahuja, Satyam Agarwal, Gaurav Khanna, Arjun Khanna","doi":"10.4103/lungindia.lungindia_417_23","DOIUrl":"10.4103/lungindia.lungindia_417_23","url":null,"abstract":"<p><strong>Abstract: </strong>Non-resolving consolidation refers to the persistence of radiographic abnormalities beyond the anticipated timeframe. Conditions such as infection, malignancy, inflammatory disorders, and connective tissue diseases can all manifest as non-resolving consolidation. We share a clinicopathological case study involving a 30-year-old male who exhibits non-resolving consolidation accompanied by hepatosplenomegaly.</p>","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 4","pages":"299-304"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302775/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of alpha-defensins as a marker of severity in chronic obstructive pulmonary disease.","authors":"Kritika Kumar, Komaldeep Kaur, Shivani Jaswal, Deepak Aggarwal, Varinder Saini","doi":"10.4103/lungindia.lungindia_395_23","DOIUrl":"10.4103/lungindia.lungindia_395_23","url":null,"abstract":"<p><strong>Background: </strong>Defensins are key effector molecules of innate immunity that can contribute towards the diagnosis and monitoring of chronic obstructive pulmonary disease (COPD). The present study was conducted to investigate the role of alpha-defensins in patients with COPD by quantifying serum and sputum samples.</p><p><strong>Methods: </strong>A total of 180 patients were enrolled and divided into four groups, and sputum and serum values of alpha-defensins were assessed. The sensitivity, specificity, and accuracy of sputum alpha-defensin as a diagnostic biomarker were evaluated to assess its utility in diagnosing COPD.</p><p><strong>Results: </strong>The mean value of sputum alpha-defensins was found to be statistically significant amongst the four groups (P < 0.001). The highest levels were found in subjects with AECOPD (385.76 ± 116.62 ng/mL). Sputum alpha-defensins were found to be negatively correlated with FEV 1 values (rho = -0.31, P < 0.001).</p><p><strong>Conclusion: </strong>Sputum alpha-defensins can be used as a potential marker for predicting acute exacerbation of COPD. In addition, they could serve as an indicator of disease severity in COPD patients.</p>","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 4","pages":"259-264"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302783/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Positive airway pressure (PAP) as a remedy for treatment-resistant migraine - A case report.","authors":"Bavneet Kaur, Kaustav Kundu, Purushottam Singh, Lokesh K Saini, Ravi Gupta","doi":"10.4103/lungindia.lungindia_22_24","DOIUrl":"10.4103/lungindia.lungindia_22_24","url":null,"abstract":"","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 4","pages":"322-324"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert panel opinion on adult pneumococcal vaccination in the post-COVID era (NAP- EXPO Recommendations-2024).","authors":"Parvaiz A Koul, Agam C Vora, Surinder K Jindal, Venkatasubramanian Ramasubramanian, Varsha Narayanan, Surya Kant Tripathi, Digambar Bahera, Harway Bhaskar Chandrashekhar, Ravindra Mehta, Narendra Raval, Prabhakar Dorairaj, Prashant Chhajed, Akash Balki, Rohan Ketan Aurangabadwalla, Abhijeet Khandelwal, Mahendra Kawedia, Satya Prakash Rai, Ashok Grover, Manish Sachdev, Surajit Chatterjee, Velamuru V Ramanaprasad, Aratrika Das, Mahavir Madhavdas Modi","doi":"10.4103/lungindia.lungindia_8_24","DOIUrl":"10.4103/lungindia.lungindia_8_24","url":null,"abstract":"<p><strong>Introduction: </strong>Pneumococcal diseases pose a significant public health concern in India, with substantial morbidity and mortality, with the elderly and those with coexisting medical conditions being most at risk. Pneumococcus was also seen to be one of the main reasons for co-infection, pneumonia and complications in COVID. Current guidelines recommend vaccination for specific adult populations, but there is a lack of uniformity and guidance on risk stratification, prioritisation and optimal timing.</p><p><strong>Methods: </strong>Nation Against Pneumococcal Infections - Expert Panel Opinion (NAP-EXPO) is a panel convened to review and update recommendations for adult pneumococcal vaccination in India. The panel of 23 experts from various medical specialties engaged in discussions and evidence-based reviews, discussed appropriate age for vaccination, risk stratification for COPD and asthma patients, vaccination strategies for post-COVID patients, smokers and diabetics, as well as methods to improve vaccine awareness and uptake.</p><p><strong>Outcome: </strong>The NAP-EXPO recommends the following for adults: All healthy individuals 60 years of age and above should receive the pneumococcal vaccine; all COPD patients, regardless of severity, high-risk asthma patients, post-COVID cases with lung fibrosis or significant lung damage, should be vaccinated with the pneumococcal vaccine; all current smokers and passive smokers should be educated and offered the pneumococcal vaccine, regardless of their age or health condition; all diabetic individuals should receive the pneumococcal vaccine, irrespective of their diabetes control. Strategies to improve vaccine awareness and uptake should involve general practitioners (GPs), primary health physicians (PHPs) and physicians treating patients at high risk of pneumococcal disease. Advocacy campaigns should involve media, including social media platforms.</p><p><strong>Conclusion: </strong>These recommendations aim to enhance pneumococcal vaccination coverage among high-risk populations in India in order to ensure a reduction in the burden of pneumococcal diseases, in the post-COVID era. There is a need to create more evidence and data to support the recommendations that the vaccine will be useful to a wider range of populations, as suggested in our consensus.</p>","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 4","pages":"307-317"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of COVID-19 pandemic on influenza vaccine uptake.","authors":"Vidya B Nair, Sujith Varghese Abraham, Arjun Padmanabhan","doi":"10.4103/lungindia.lungindia_510_23","DOIUrl":"10.4103/lungindia.lungindia_510_23","url":null,"abstract":"","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 4","pages":"327-328"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The severity of non-smoking chronic obstructive pulmonary disease is correlated with biomass fuel exposure and COPD assessment test score.","authors":"Anuj Kumar Pandey, Ajay Kumar Verma, Arpita Singh, Surya Kant, Shyam Chand Chaudhary, Jyoti Bajpai, Rakesh Kumar Dixit","doi":"10.4103/lungindia.lungindia_304_23","DOIUrl":"10.4103/lungindia.lungindia_304_23","url":null,"abstract":"<p><strong>Background and objective: </strong>Tobacco smoking is an established risk factor for chronic obstructive pulmonary disease (COPD). Current evidence suggests that non-tobacco-related risk factors vary geographically and are less understood than smoking. This study aims to compare the risk factors, symptoms, and clinical features of smoking (S-COPD) and non-smoking (NS-COPD) in a COPD population.</p><p><strong>Materials and methods: </strong>In this retrospective cross-sectional study, 489 COPD patients were screened. Data on socio-demographics, smoking and medical history, other risk factors, symptoms, and clinical characteristics including COPD Assessment Test (CAT) score, and Modified Medical Research Council (mMRC) Dyspnea Scale were examined.</p><p><strong>Results: </strong>Of the total selected 416 COPD patients, 35.34% were NS-COPD while 64.66% were S-COPD. S-COPD was predominant in males, whereas NS-COPD was predominant in females (P < 0.0001). In NS-COPD, biomass fuel exposure was a major risk factor (P < 0.0001), and 61% of subjects had a biomass fuel exposure index of >60. In bivariate and multivariate analyses, no risk factors were correlated with forced expiratory volume in 1 second (FEV1)% predicted, while among clinical features, duration of illness (P = 0.001) was correlated with lower values of FEV1 in the multivariate table of S-COPD. In the multivariate analysis, biomass fuel exposure (P = 0.039) and CAT score (P < 0.0001) were correlated with FEV1(%) in NS-COPD.</p><p><strong>Conclusion: </strong>Biomass fuel exposure is a substantial risk factor for NS-COPD and was correlated with FEV1(%) predicted. In addition, the CAT score correlated with disease severity in patients with NS-COPD. The development of COPD in non-smokers is being recognized as a separate phenotype and it should be managed according to risk factors.</p>","PeriodicalId":47462,"journal":{"name":"Lung India","volume":"41 4","pages":"251-258"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}